Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 2/20 | 0.36 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7407101 | 0.81 | ALDH1A1 (0.45) | ALDH1A1KDM4ENPC1RAB9ABRAF | |
| SCHEMBL2004766 | 0.81 | NPC1 (0.52) | ALDH1A1KDM4ENPC1RAB9ABRAF | |
| SCHEMBL5838309 | 0.80 | NPC1 (0.42) | ALDH1A1KDM4ENPC1RAB9ABRAF | |
| SCHEMBL1937210 | 0.80 | RAB9A (0.46) | ALDH1A1KDM4ENPC1RAB9AKMT2A | |
| SCHEMBL262815 | 0.80 | — | — | |
| SCHEMBL9442082 | 0.78 | NPC1 (0.50) | ALDH1A1KDM4ENPC1RAB9ABRAF | |
| SCHEMBL5829402 | 0.77 | NPC1 (0.48) | ALDH1A1KDM4ENPC1RAB9ABRAF | |
| SCHEMBL5324109 | 0.75 | NPC1 (0.47) | ALDH1A1KDM4ENPC1RAB9AKMT2A | |
| SCHEMBL10784714 | 0.74 | NPC1 (0.47) | ALDH1A1KDM4ENPC1RAB9ABRAF | |
| SCHEMBL5160052 | 0.74 | NPC1 (0.44) | ALDH1A1KDM4ENPC1RAB9ABRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319292-B2 | Metabolically stable 5-HMF derivatives for the treatment of hypoxia | KING ABDULAZIZ UNIVERSITY (SA) | 2022-05-03 | — | — | US | disclosed |
| US-11319292-B2 | Metabolically stable 5-HMF derivatives for the treatment of hypoxia | KING ABDULAZIZ UNIVERSITY (SA) | 2022-05-03 | — | — | US | disclosed |
| US-20210403434-A1 | METABOLICALLY STABLE 5-HMF DERIVATIVES FOR THE TREATMENT OF HYPOXIA | VIRGINIA COMMONWEALTH UNIVERSITY | 2021-12-30 | — | — | US | disclosed |
| US-20210403434-A1 | METABOLICALLY STABLE 5-HMF DERIVATIVES FOR THE TREATMENT OF HYPOXIA | VIRGINIA COMMONWEALTH UNIVERSITY | 2021-12-30 | — | — | US | disclosed |
| US-20210340109-A1 | METABOLICALLY STABLE 5-HMF DERIVATIVES FOR THE TREATMENT OF HYPOXIA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-11-04 | — | — | US | disclosed |
| US-11149012-B1 | Metabolically stable 5-HMF derivatives for the treatment of hypoxia | KING ABDULAZIZ UNIVERSITY (SA) | 2021-10-19 | — | — | US | disclosed |
| US-11149012-B1 | Metabolically stable 5-HMF derivatives for the treatment of hypoxia | KING ABDULAZIZ UNIVERSITY (SA) | 2021-10-19 | — | — | US | disclosed |
| US-10836729-B1 | Metabolically stable 5-HMF derivatives for the treatment of hypoxia | KING ABDULAZIZ UNIVERSITY (SA) | 2020-11-17 | — | — | US | disclosed |
| US-10836729-B1 | Metabolically stable 5-HMF derivatives for the treatment of hypoxia | KING ABDULAZIZ UNIVERSITY (SA) | 2020-11-17 | — | — | US | disclosed |
| US-6362192-B1 | FOR PLANTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-03-26 | — | — | US | disclosed |
| US-5221762-A | Reacting a phenol with benzolactone compound; then phosgene or thionyl chloride; esterification with alcohol | BASF AKTIENGESELLSCHAFT (DE) | 1993-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340109-A1 | METABOLICALLY STABLE 5-HMF DERIVATIVES FOR THE TREATMENT OF HYPOXIA | HIF1AN, HMOX2, HIF1A | ALDH1A1 307/4885KDM4E 742/4885NPC1 2788/4885 |
| US-11149012-B1 | Metabolically stable 5-HMF derivatives for the treatment of hypoxia | HIF1AN, HMOX2, HIF1A | ALDH1A1 307/4885KDM4E 742/4885NPC1 2788/4885 |
| US-10836729-B1 | Metabolically stable 5-HMF derivatives for the treatment of hypoxia | HIF1AN, HMOX2, HIF1A | ALDH1A1 307/4885KDM4E 742/4885NPC1 2788/4885 |
| US-11319292-B2 | Metabolically stable 5-HMF derivatives for the treatment of hypoxia | HIF1AN, HMOX2, HIF1A | ALDH1A1 307/4885KDM4E 742/4885NPC1 2788/4885 |
| US-20210403434-A1 | METABOLICALLY STABLE 5-HMF DERIVATIVES FOR THE TREATMENT OF HYPOXIA | HIF1AN, HMOX2, HIF1A | ALDH1A1 307/4885KDM4E 742/4885NPC1 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.